INDRAYANI BIOTECH LTD.

Indrayani Biotech Ltd has announced a delay in the declaration of its audited financial results (standalone & consolidated) for the quarter and year ended March 31, 2026. The company cites consolidation of subsidiary results, operational disruptions, and the completion of internal and external audit processes as reasons for the delay. The board meeting to approve the results will be held at a later date, with prior intimation to be given. The trading window will remain closed until 48 hours after the declaration of the results.

Mr. S. Indirakumar resigned from his position as Whole-Time Director of Indrayani Biotech Ltd, effective immediately. The resignation is attributed to the company's alleged failure to uphold ethical conduct, statutory compliance, and fiduciary obligations. Indirakumar, a promoter-shareholder, claims severe personal, financial, and legal harm due to the company's actions. He also alleges unethical conduct by the management, related party transactions without board approval, and exclusion from decision-making despite holding a significant shareholding.

Indrayani Biotech Ltd has revised the schedule for its partly paid-up Rights Issue. The issue, originally scheduled for May 27, 2026 to June 25, 2026, will now be open from June 25, 2026 to July 24, 2026. The last date for on-market renunciation is also revised to July 20, 2026 from June 16, 2026. Revised offer documents will be available on the BSE and company websites. All other terms of the issue remain unchanged.

Indrayani Biotech Ltd's Rights Issue Committee, at its meeting on April 28, 2026, approved crucial documents for the proposed Rights Issue. The approvals include the Letter of Offer (LOF), the Abridged Letter of Offer (ALOF), and the Composite Application Form (CAF). Additionally, the committee sanctioned the detailed instructions for the renunciation process. This development signifies progress in the company's efforts to proceed with its capital raising initiative through a Rights Issue.

Indrayani Biotech Ltd has received an assessment order from the Income Tax Department, raising a demand of ₹13.90 Crores. The company has filed an appeal before the Income Tax Appellate Tribunal (ITAT) to contest the demand. Based on legal advice, Indrayani Biotech believes the demand is not expected to have a material adverse impact on its financial operations. The matter is currently sub-judice, and the company is awaiting the date of the first hearing.

Indrayani Biotech Ltd has announced the ISIN for the Rights Entitlement related to its partly paid-up Rights Issue. This follows the Board's Rights Issue Committee meeting on April 9, 2026, which approved the key terms of the issue to eligible shareholders. The ISIN for the Rights Entitlement is INE007C20013, corresponding to partly paid-up equity shares with a face value of Rs.10/- and a paid-up value of Rs. 2.50. The company has uploaded this intimation on its official website.

Indrayani Biotech Ltd has announced the fixation of the Record Date for the Partly Paid-up Rights Issue. The Record Date has been set as 28th April, 2026. The Rights Issue Committee of the Board of Directors of the Company made this decision in a meeting held on an unspecified date. The purpose of this Record Date is to determine the equity shareholders entitled to receive the rights entitlement in the Rights Issue. The Rights Issue details include a total of 3,25,25,897 Rights Equity Shares, an issue price of ₹15 per Rights Equity Share, and a Rights Entitlement Ratio of 5 Rights Equity Shares for every 7 fully paid-up equity shares of the Company held by the Eligible Equity Shareholders.

Indrayani Biotech Ltd. has announced the outcome of the Rights Issue Committee Meeting held on 09-04-2026. The committee has approved the terms of the Rights Issue, which includes the issuance of 3,25,25,897 equity shares at a price of ₹15 per share (including a premium of ₹5 per share), amounting to ₹49.90 crore. The record date for the Rights Issue is Tuesday, 28-04-2026, and the Rights Issue period is from 27-05-2026 to 25-06-2026. The rights entitlement ratio is 5 Rights Equity Shares for every 7 fully paid-up equity shares held by the Eligible Equity Shareholders as on the record date. The company has made arrangements with NSDL and CDSL for the credits of the rights entitlements in dematerialized form in the demat account of the Eligible Equity Shareholders.

Indrayani Biotech Ltd. has announced the outcome of its Rights Issue Committee Meeting held on 9th April, 2026. The committee has approved the terms of the Rights Issue, which includes the issuance of 3,25,25,897 equity shares at a price of ₹15 per share (including a premium of ₹5 per share), amounting to ₹49.90 crore. The record date for the Rights Issue is Tuesday, 28th April, 2026, and the Rights Issue period begins on Wednesday, 27th May, 2026, and ends on Thursday, 25th June, 2026. The rights entitlement ratio is 5 Rights Equity Shares for every 7 fully paid-up equity shares held by the eligible equity shareholders as on the record date. The arrangement for the credits of the rights entitlements has been made with NSDL and CDSL for the credits of the rights entitlements with a separate ISIN in dematerialized form in the demat account of the Eligible Equity Shareholders against the equity shares held by them as on the Record Date.

Indrayani Biotech Ltd's Board meeting held on 9th April, 2026, discussed and approved a preliminary proposal for the demerger of their food division into a separate company. The Board also approved the constitution of a 'Restructuring Committee' to oversee the process, take necessary decisions, and initiate required actions. Additionally, M/S VAITHIANATHAN & ASSOCIATES, Chartered Accountants, were appointed as the Internal Auditor for the Financial Years 2025-26 and 2026-27.